This is a working overview of Lyophilization, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-10 and is reviewed periodically as new material appears.
Solvent choice depends on the peptide's sequence, charge, and solubility profile. Sterile water is common for freely soluble peptides, while aqueous buffers or dilute acid or base may be needed for others. Some sequences contain hydrophobic regions that resist water alone and require a small amount of organic co-solvent. The solvent's pH can affect charge state, aggregation, and stability. Because peptides vary widely, no single universal reconstitution liquid exists, and suppliers often provide a recommended solvent based on testing of a specific lot or sequence.
After a solvent is added, the vial is typically swirled or gently inverted rather than shaken vigorously. Shaking can introduce air and shear forces that promote foaming or aggregation, especially for longer peptides. Dissolution may take several minutes, and the solution should become clear unless the peptide is intentionally in suspension. Concentration is calculated from the mass of peptide stated on the vial label divided by the total liquid volume. If the dried peptide contains salts or counterions, the actual peptide content may be lower than the nominal mass.
Cloudiness, particles, or gel formation after reconstitution can signal incomplete dissolution, aggregation, or contamination. A clear solution is not proof of purity, and a cloudy one is not always unusable if the peptide is designed to form suspensions. pH measurement can identify whether the solution matches the intended range, and buffer exchange may be needed when the original solvent is incompatible. Sterile filtration is sometimes used for microbial control, but filters can adsorb peptides and reduce concentration. Documentation of lot number, solvent, volume, date, and storage condition supports later traceability in laboratory records.
Once a peptide is in liquid form, its stability depends on temperature, pH, concentration, and the presence of oxygen or microbes. Refrigeration slows many degradation pathways, while freezing can extend storage for longer periods. Repeated freeze-thaw cycles are generally avoided because ice crystal formation and concentration changes can promote aggregation. Light exposure can also damage peptides that contain aromatic or sulfur-containing residues. A common laboratory practice is to divide a reconstituted stock into single-use aliquots before freezing, but the optimal storage condition remains peptide-specific and is often determined empirically.
| Property | Value | Notes |
|---|---|---|
| Physical state before solvent | Lyophilized powder or cake | Freeze-drying removes water under vacuum and leaves a porous solid. |
| Common reconstitution liquid | Sterile water or aqueous buffer | Compatibility depends on peptide sequence, charge, and pH requirements. |
| Typical solution pH | pH 3 to 7 | Acidic or slightly acidic conditions are common; some peptides need other ranges. |
| Appearance after dissolution | Clear to slightly opalescent solution | Cloudiness can indicate incomplete dissolution, aggregation, or undissolved excipients. |
| Concentration basis | Mass of peptide per volume of solvent | Label mass may include counterions or salts, so peptide content can differ. |
The choice of liquid depends on peptide sequence, counterion content, and intended analysis. Water is sufficient for many hydrophilic peptides, while hydrophobic sequences may need a small amount of organic solvent or a buffer. pH can affect charge, solubility, and stability, so the target value is usually selected for the specific peptide. Exact laboratory protocols vary by supplier and application, and no single solvent reliably works for every different peptide.
Reconstitution involves considerably more than simply adding liquid. The solid must wet completely, and gentle mixing should avoid foaming, which can denature some peptides. Insoluble particles may indicate incomplete dissolution, aggregation, or insoluble excipients. The resulting concentration is calculated from the weighed peptide mass and the final volume, not from the volume of liquid added alone. Because peptides can adsorb to surfaces, container material and transfer steps can influence recovery, especially at low concentrations.
Reconstitution is the process of dissolving a lyophilized peptide powder in a suitable liquid to produce a solution for laboratory or clinical use. The dry powder is typically a porous cake or fluffy solid formed by freeze-drying an aqueous or mixed-solvent preparation. Adding solvent restores the peptide to a dissolved state, but the result is not necessarily identical to the original pre-lyophilization solution. Factors such as pH, ionic strength, temperature, and the peptide's sequence influence how completely and quickly dissolution occurs. The term is distinct from dilution, which lowers concentration without changing the physical state of an already dissolved material.
Solvent selection depends on the peptide's charge, hydrophobicity, and intended application. Many lyophilized peptides dissolve readily in water, while others require a small amount of a miscible organic solvent, a dilute acid, or a dilute base before aqueous dilution. A buffer may be used when a stable pH range is known, but adding buffer salts can also promote aggregation or precipitation. Dissolution should be observed rather than assumed, because a clear solution does not prove that the peptide is monomeric or fully active. The order of solvent addition and the final volume matter for achieving the intended concentration.
After a peptide is reconstituted, analytical checks can confirm identity, concentration, and purity. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry provides a mass value that supports sequence identity, while ultraviolet absorbance at 214 or 280 nanometers is often used for concentration estimation when the extinction coefficient is known. These methods answer different questions and are complementary. A single measurement rarely establishes full quality, because the same sample can appear acceptable by one method and fail another.
Concentration calculations depend on the amount of peptide present in the vial and the volume of solvent added. Lyophilized preparations often contain counterions, salts, or residual water, so the labeled mass may not equal the mass of the peptide itself. This difference can produce a calculated concentration that is higher than the true peptide concentration. Analytical determination of peptide content, rather than reliance on the vial label alone, reduces this source of error. Uncertainty in volume measurement also contributes, especially when small liquid volumes are handled.
Quality records typically include a certificate of analysis, batch number, molecular weight, purity result, and recommended storage conditions. After reconstitution, a laboratory log may record solvent, final volume, date, and storage location. Such documentation supports reproducibility and allows later investigation if a preparation behaves unexpectedly. Stability studies often examine purity and concentration over time under defined temperatures, but results are not universally transferable between peptides or formulations. Open questions remain about how best to predict aggregation for specific sequences and how much analytical testing is sufficient for routine laboratory work.
== History == This compound was first synthesized by researchers in the Soviet Union in the early 1960s, and was subsequently investigated for glaucoma therapy. It was introduced in European ophthalmology by the late 1960s. In several European countries, it was marketed by Chibret under the trade name Glaucostat. Although not approved in the United States at that time, it was used clinically in other countries as a topical agent to lower intraocular pressure. By the 1970s, it was available under various brand names, including Glaucostat, Glaucotat, Glaunorm, and Glaudin. A combination product with epinephrine was also marketed as Glaucadrine. These formulations were used to manage glaucoma, particularly in cases where miosis facilitates a reduction in intraocular pressure.
Afamelanotide, sold under the brand name Scenesse, is a medication used to prevent phototoxicity and to reduce pain from light exposure for people with erythropoietic protoporphyria, a rare form of genetic sun sensitivity. Afamelanotide is a melanocortin 1 receptor (MC1 receptor) agonist and a synthetic peptide and analogue of α-melanocyte stimulating hormone. It is administered as subcutaneous implant. In the European Union, afamelanotide is indicated for the prevention of phototoxicity in adults with erythropoietic protoporphyria. In the United States, afamelanotide is indicated for increasing pain-free light exposure in adults with a history of reactions to light (phototoxicity) from erythropoietic protoporphyria.
The structure of CARD11 involves multiple domains that impact the protein's ability to activate BCL10 and NF-κB activity. CARD11 has a CARD domain, a serine-threonine rich region, is associated with the N-terminus, which is essential for NF-κB signaling activity. The region following the CARD domain is highly coiled. In deleting the CARD domain, all NF-κB signaling activity was prevented. The CARD domain on CARD11 interacts with the CARD domain on BCL10 to initiate the signaling pathway. On the C-terminus of CARD11 there is the MAGUK domain that is associated with the cell membrane. This domain is often referred to as the inhibitory domain. Protein kinase C activates CARD11 by phosphorylating serine residues within the inhibitory domain. CARD11 has been shown to interact with BCL10. This interaction occurs between the CARD domain on BCL10 and the CARD domain on CARD11, and results in signal propagation and NF-κB activation. Human CARD11 genome location and CARD11 gene details page in the UCSC Genome Browser.
The sulfur cycle is a biogeochemical cycle in which the sulfur moves between rocks, waterways and living systems. It is important in geology as it affects many minerals and in life because sulfur is an essential element (CHNOPS), being a constituent of many proteins and cofactors, and sulfur compounds can be used as oxidants or reductants in cellular respiration. The global sulfur cycle involves the transformations of sulfur species through different oxidation states, which play an important role in both geological and biological processes. Steps of the sulfur cycle are: Mineralization of organic sulfur into inorganic forms, such as hydrogen sulfide (H2S), elemental sulfur, as well as sulfide minerals. Incorporation of sulfide into organic compounds (including metal-containing derivatives). Oxidation of hydrogen sulfide, sulfide, and elemental sulfur (S) to sulfate (SO2−4). Reduction of sulfate and sulfite to sulfide. Disproportionation of sulfur compounds (elemental sulfur, sulfite, thiosulfate) into sulfate and hydrogen sulfide. These are often termed as follows:
Cadmium is a strong neutron poison and in fact control rods are often made out of cadmium, making the accumulation of cadmium in fuel of particular concern for the maintenance of stable neutron economy. Cadmium is also a chemically poisonous heavy metal, but given the number of neutron absorptions required for transmutation, it is not a high priority target for deliberate transmutation.
Sources: en.wikipedia.org
== Veterinary use == After the discontinuation of lente insulin for human use, the FDA approved a veterinary porcine-derived lente insulin (Vetsulin®, Merck Animal Health) for daily use in dogs or twice daily use in cats. Insulin analogs used in humans after the discontinuation of lente insulin have not yet been proven to provide the same benefits and predictability as lente insulin in cats and dogs. For this and other reasons, lente insulin is still commonly used in both dogs and cats.
== Research == Examples of ongoing government research organizations to better understand the potential health properties and safety of dietary supplements are the European Food Safety Authority, the Office of Dietary Supplements of the United States National Institutes of Health, the Natural and Non-prescription Health Products Directorate of Canada, and the Therapeutic Goods Administration of Australia. Together with public and private research groups, these agencies construct databases on supplement properties, perform research on quality, safety, and population trends of supplement use, and evaluate the potential clinical efficacy of supplements for maintaining health or lowering disease risk.
=== Liver toxicity and urologic disease === Urologic diseases occur primarily in people who use large amounts of ketamine routinely, with 20–30% of frequent users having bladder complaints. It includes a range of disorders from cystitis to hydronephrosis to kidney failure. The typical symptoms of ketamine-induced cystitis are frequent urination, dysuria, and urinary urgency sometimes accompanied by pain during urination and blood in urine. The damage to the bladder wall has similarities to both interstitial and eosinophilic cystitis. The wall is thickened and the functional bladder capacity is as low as 10–150 mL. Studies indicate that ketamine-induced cystitis is caused by ketamine and its metabolites directly interacting with urothelium, resulting in damage of the epithelial cells of the bladder lining and increased permeability of the urothelial barrier which results in clinical symptoms. Management of ketamine-induced cystitis involves ketamine cessation as the first step. This is followed by NSAIDs and anticholinergics and, if the response is insufficient, by tramadol. The second-line treatments are epithelium-protective agents such as oral pentosan polysulfate or intravesical instillation of hyaluronic acid. Intravesical botulinum toxin is also useful. Some research also indicates that epigallocatechin-3-gallate (EGCG) may mitigate bladder dysfunction in ketamine-induced cystitis by normalizing the collagen-to-muscle ratio and restoring storage capacity. Hepatotoxicity (toxicity to the liver) of ketamine involves higher doses and repeated administration.
Because polypeptide hormones are not fat-soluble, they cannot penetrate cell membranes. Thus, GH exerts some of its effects by binding to receptors on target cells, where it activates the MAPK/ERK pathway. Through this mechanism GH directly stimulates division and multiplication of chondrocytes of cartilage. GH also stimulates, through the JAK-STAT signaling pathway, the production of insulin-like growth factor 1 (IGF-1, formerly known as somatomedin C), a hormone homologous to proinsulin. The liver is a major target organ of GH for this process and is the principal site of IGF-1 production. IGF-1 has growth-stimulating effects on a wide variety of tissues. Additional IGF-1 is generated within target tissues, making it what appears to be both an endocrine and an autocrine/paracrine hormone. IGF-1 also has stimulatory effects on osteoblast and chondrocyte activity to promote bone growth. In addition to increasing height in children and adolescents, growth hormone has many other effects on the body:
Sources: en.wikipedia.org
Di Prisco G, Casola L, Giuditta A (1967). "Purification and properties of a soluble reduced nicotinamide-adenine dinucleotide (phosphate) dehydrogenase from the hepatopancreas of Octopus vulgaris". Biochem. J. 105 (2): 455–60. doi:10.1042/bj1050455. PMC 1198331. PMID 4171422. GIUDITTA A, STRECKER HJ (1961). "Purification and some properties of a brain diaphorase". Biochim. Biophys. Acta. 48: 10–9. doi:10.1016/0006-3002(61)90509-1. PMID 13705804. MAERKI F, MARTIUS C (1960). "[Vitamin K reductase, preparation and properties.]". Biochem. Z. 333: 111–35. PMID 13765127. Misaka E, Nakanishi K. "Studies on menadione reductase of bakers' yeast. I. Purification, crystallization and some properties". J. Biochem. Tokyo: 465–471. WOSILAIT WD (1960). "The reduction of vitamin K1 by an enzyme from dog liver". J. Biol. Chem. 235 (4): 1196–201. doi:10.1016/S0021-9258(18)69504-3. PMID 13846011. Sparla F, Tedeschi G, Trost P (1996). "NAD(P)H:(Quinone-Acceptor) Oxidoreductase of Tobacco Leaves Is a Flavin Mononucleotide-Containing Flavoenzyme". Plant Physiol. 112 (1): 249–258. doi:10.1104/pp.112.1.249. PMC 157943. PMID 12226388. Braun M, Bungert S, Friedrich T (1998). "Characterization of the overproduced NADH dehydrogenase fragment of the NADH:ubiquinone oxidoreductase (complex I) from Escherichia coli". Biochemistry. 37 (7): 1861–7. doi:10.1021/bi971176p. PMID 9485311. Jaiswal AK (2000). "Characterization and partial purification of microsomal NAD(P)H:quinone oxidoreductases". Arch. Biochem. Biophys. 375 (1): 62–8. doi:10.1006/abbi.1999.1650. PMID 10683249.
== Uses == Whey is used to produce whey cheeses such as ricotta, Norwegian brunost, and whey butter and many other products for human consumption. The fat content of whey is low; 1,000 pounds of whey are required to make a few pounds of whey butter. It is also an additive in many processed foods, including breads, crackers, and commercial pastry, and in animal feed. Whey proteins consist primarily of α-lactalbumin and β-lactoglobulin. Sweet whey contains glycomacropeptide (GMP). It is also an abundant source of lactose which can further be used for the synthesis of lactose-based bioactive molecules. Dairy whey remaining from home-made cheesemaking has many uses. It is a dough conditioner and can be substituted for skimmed milk in most baked good recipes that require milk (bread, pancakes, muffins, etc.). Throughout history, whey was a popular drink in inns and coffee houses. When Joseph Priestley was at college at Daventry Academy, 1752–1755, he records that, on the morning of Wednesday, 22 May 1754, he "went with a large company to drink whey." This was probably "sack whey" or "wine whey". Whey is also one of the main ingredients of Rivella, a carbonated drink in Switzerland. In areas where cheese is made, excess whey byproduct is sometimes sprayed over hay fields as a fertilizer. Historically whey, being a byproduct of cheese making, was considered a waste product and was pumped into rivers and streams in the U.S. Since the whey contained protein, this practice led to the growth of large concentrations of algae.
is the dimensionality of the system. Examples include charge-charge interactions between ions and dipole-dipole interactions between molecules. Modelling these forces presents quite a challenge as they are significant over a distance which may be larger than half the box length with simulations of many thousands of particles. Though one solution would be to significantly increase the size of the box length, this brute force approach is less than ideal as the simulation would become computationally very expensive. Spherically truncating the potential is also out of the question as unrealistic behaviour may be observed when the distance is close to the cut off distance. The most important long-range interactions are electrostatic interactions between two (partly) charge atoms. At present, the most used method is Particle Mesh Ewald (PME). PME uses Ewald summations to split the calculations into a short- and long range part. The short-range part calculates all interactions within a cut-off range, the long-range part is solved in reciprocal space, using fast Fourier transforms (FFTs). The high accuracy and high calculation speed made PME the gold standard for many years. However the increase use of parallelization, PME runs into a communication bottleneck because the FFTs require an all-to-all communication. A attractive PME alternative are the fast multipole methods (FMM), which are not affected by an increase in parallelization.
Sources: en.wikipedia.org
Reconstitution means adding a liquid to a dried peptide to form a solution. The dried material is usually a lyophilized powder or cake produced by freeze-drying. The resulting liquid is a stock solution that can be diluted or analyzed further.
Freeze-drying removes water and limits hydrolysis and oxidation during storage. The dried solid is generally more stable and easier to ship than a liquid. It also allows a defined amount of material to be sealed in a single vial.
No. Solubility depends on the amino acid sequence, charge, and hydrophobic content. Some peptides require buffer, dilute acid, dilute base, or a small amount of organic solvent. A supplier's recommended solvent is based on the specific peptide.
Short-term storage is often under refrigeration, while longer storage may use freezing at -20 °C or lower. The choice depends on peptide stability and the solvent. Dividing the solution into aliquots reduces repeated temperature changes.